TScan Therapeutics, Inc.TCRXEarnings & Financial Report
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.
Revenue
$3.9M
Gross Profit
N/A
Operating Profit
$-24.7M
Net Profit
$-23.0M
Gross Margin
N/A
Operating Margin
-636.7%
Net Margin
-591.6%
YoY Growth
15.6%
EPS
$-0.24
TScan Therapeutics, Inc. Q3 FY2023 Financial Summary
TScan Therapeutics, Inc. reported revenue of $3.9M (up 15.6% YoY) for Q3 FY2023, with a net profit of $-23.0M (down 41.6% YoY) (-591.6% margin).
Key Financial Metrics
| Total Revenue | $3.9M |
|---|---|
| Net Profit | $-23.0M |
| Gross Margin | N/A |
| Operating Margin | -636.7% |
| Report Period | Q3 FY2023 |
TScan Therapeutics, Inc. Annual Revenue by Year
TScan Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $10.3M).
| Year | Annual Revenue |
|---|---|
| 2025 | $10.3M |
| 2023 | $21.0M |
| 2022 | $13.5M |
TScan Therapeutics, Inc. Quarterly Revenue & Net Profit History
TScan Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.6M | +286.0% | $-23.0M | -895.1% |
| Q3 FY2025 | $2.5M | +139.4% | $-35.7M | -1422.1% |
| Q2 FY2025 | $3.1M | +473.9% | $-37.0M | -1201.3% |
| Q1 FY2025 | $2.2M | +283.6% | $-34.1M | -1571.9% |
| Q3 FY2024 | $1.0M | -73.0% | $-29.9M | -2849.1% |
| Q4 FY2023 | $7.2M | +133.0% | $-19.6M | -272.0% |
| Q3 FY2023 | $3.9M | +15.6% | $-23.0M | -591.6% |
| Q2 FY2023 | $3.1M | -22.4% | $-24.0M | -763.8% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $3.9M | $7.2M | $1.0M | $2.2M | $3.1M | $2.5M | $2.6M |
| YoY Growth | -22.4% | 15.6% | 133.0% | -73.0% | 283.6% | 473.9% | 139.4% | 286.0% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $316.9M | $291.4M | $272.1M | $348.0M | $332.7M | $298.6M | $262.2M | $228.8M |
| Liabilities | $126.3M | $122.4M | $121.3M | $118.9M | $122.5M | $121.8M | $118.2M | $105.7M |
| Equity | $190.6M | $169.0M | $150.9M | $229.1M | $210.2M | $176.7M | $144.0M | $123.1M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-22.0M | $8.0M | $-23.8M | $-27.9M | $-37.6M | $-33.3M | $-32.5M | $-32.0M |